 |
|
Genome of Clostridium botulinum reveals the background to world's deadliest toxin
May 29, 2007The genome of the organism that produces the world's most lethal toxin is revealed today. This toxin is the one real weapon in the genome of Clostridium botulinum and less than 2 kg - the weight of two bags of sugar - is enough to kill every person on the planet. Very small amounts of the same toxin are used in medical treatments, one of which is known as Botox®.
The genome sequence shows that C. botulinum doesn't have subtle tools to evade our human defences or tricky methods of acquiring resistance to antibiotics. It lives either as a dormant spore or as a scavenger of decaying animal materials in the soil, and doesn't interact with human or other large animal hosts for prolonged periods of time.
Occasionally it gets into a living animal, via contaminated food or open wounds, leading to infant botulism or wound botulism, both of which are serious human infections. The host can be quickly overpowered and, in some cases, killed by the toxin, and C. botulinum has a new food source.
"Although in the same group as Clostridium difficile - the Cdiff superbug - C. botulinum has a genome that is remarkable because it is so stable," commented Dr Mohammed Sebaihia, lead author on the paper from the Wellcome Trust Sanger Institute. "Unlike Cdiff, in which more than 10 per cent of genes have been acquired from other bacteria, there is almost no footprint of these in C. botulinum."
There are several types of C. botulinum: although described as variants of a single species, they are really very different organisms linked simply because they have the deadly toxin. For each type, there is also a near-identical but harmless relative that lacks the toxin. C. sporogenes is the non-malignant, near twin of the organism sequenced.
Professor Mike Peck, from the Institute of Food Research, commented that "It is astonishing that 43 per cent of the predicted genes in the C. botulinum genome are absent from the other five sequenced clostridia, and only 16 per cent of the C. botulinum genes are common to all five. Our findings emphasise just how different clostridia are from each other."
C. botulinum toxin stops nerves from working - the basis of its use in medicine to control tremors and in cosmetic treatments. For the prey of its opportunistic attacks, death is swift. Perhaps the most important tool it has to act out its stealth attacks is its ability to hibernate when times are hard by forming dormant spores.
More than 110 of its set of almost 3700 genes are used to control spore formation and germination when opportunity arises.
"C. botulinum shows us one extreme of the ways that bacteria can make the most of animal hosts," explained Dr Julian Parkhill of the Wellcome Trust Sanger Institute. "Some organisms use subtle approaches, elegantly choreographing their interaction with us and our defences.
"C. botulinum takes the opposite approach. It lies in wait and, if it gets the opportunity, it hits its host with a microbial sledgehammer. It then eats the remains and lays low until the next host comes along."
The genome sequence is peppered with genes that produce enzymes to digest proteins and other animal material in the soil. Also found, uniquely in this species, is a range of genes that allow it to attack the many insect and other small creatures that live in the soil. The 'chitinases' produced by these genes can degrade the casing of insects and small crustaceans.
It is not only animals that can feel the wrath of C. botulinum, explains Dr Sebaihia: "The soil can be a harsh environment and food can be scarce. To see off the competition, C. botulinum comes with its own 'antibiotic' - a chemical called boticin that kills competing bacteria."
Genome sequences can tell us a lot about the biology of the organism, but research into clostridia has been hampered by the lack of a good genetic system. Professor Nigel Minton, Professor of Applied Molecular Microbiology at The University of Nottingham, has developed new methods to knock out genes in clostridia.
"Even after decades of research, only a handful of mutants had been made in clostridia, and none in C. botulinum," Professor Minton explains. "We have developed a highly efficient system, the ClosTron, with which we have, in a few months, knocked out over 30 genes in four different clostridial species, including eight in C. botulinum. The availability of this tool should revolutionise functional genomic studies in clostridia."
This remarkable, stable genome demonstrates the wide range of strategies used by bacteria to enhance their chances of survival. For the Clostridia, these range from the approach used by Cdiff - long-term interaction with hosts, which involves evading the immune system and countering antibiotics - to the single-minded opportunistic approach of C. botulinum.
University of Nottingham
"Although in the same group as Clostridium difficile - the Cdiff superbug - C. botulinum has a genome that is remarkable because it is so stable," commented Dr Mohammed Sebaihia, lead author on the paper from the Wellcome Trust Sanger Institute. "Unlike Cdiff, in which more than 10 per cent of genes have been acquired from other bacteria, there is almost no footprint of these in C. botulinum."
There are several types of C. botulinum: although described as variants of a single species, they are really very different organisms linked simply because they have the deadly toxin. For each type, there is also a near-identical but harmless relative that lacks the toxin. C. sporogenes is the non-malignant, near twin of the organism sequenced.
Professor Mike Peck, from the Institute of Food Research, commented that "It is astonishing that 43 per cent of the predicted genes in the C. botulinum genome are absent from the other five sequenced clostridia, and only 16 per cent of the C. botulinum genes are common to all five. Our findings emphasise just how different clostridia are from each other."
C. botulinum toxin stops nerves from working - the basis of its use in medicine to control tremors and in cosmetic treatments. For the prey of its opportunistic attacks, death is swift. Perhaps the most important tool it has to act out its stealth attacks is its ability to hibernate when times are hard by forming dormant spores.
More than 110 of its set of almost 3700 genes are used to control spore formation and germination when opportunity arises.
"C. botulinum shows us one extreme of the ways that bacteria can make the most of animal hosts," explained Dr Julian Parkhill of the Wellcome Trust Sanger Institute. "Some organisms use subtle approaches, elegantly choreographing their interaction with us and our defences.
"C. botulinum takes the opposite approach. It lies in wait and, if it gets the opportunity, it hits its host with a microbial sledgehammer. It then eats the remains and lays low until the next host comes along."
The genome sequence is peppered with genes that produce enzymes to digest proteins and other animal material in the soil. Also found, uniquely in this species, is a range of genes that allow it to attack the many insect and other small creatures that live in the soil. The 'chitinases' produced by these genes can degrade the casing of insects and small crustaceans.
It is not only animals that can feel the wrath of C. botulinum, explains Dr Sebaihia: "The soil can be a harsh environment and food can be scarce. To see off the competition, C. botulinum comes with its own 'antibiotic' - a chemical called boticin that kills competing bacteria."
Genome sequences can tell us a lot about the biology of the organism, but research into clostridia has been hampered by the lack of a good genetic system. Professor Nigel Minton, Professor of Applied Molecular Microbiology at The University of Nottingham, has developed new methods to knock out genes in clostridia.
"Even after decades of research, only a handful of mutants had been made in clostridia, and none in C. botulinum," Professor Minton explains. "We have developed a highly efficient system, the ClosTron, with which we have, in a few months, knocked out over 30 genes in four different clostridial species, including eight in C. botulinum. The availability of this tool should revolutionise functional genomic studies in clostridia."
This remarkable, stable genome demonstrates the wide range of strategies used by bacteria to enhance their chances of survival. For the Clostridia, these range from the approach used by Cdiff - long-term interaction with hosts, which involves evading the immune system and countering antibiotics - to the single-minded opportunistic approach of C. botulinum.
University of Nottingham
Botulinum Current Events and Botulinum News RSSNew guidelines identify best treatments to help ALS patients live longer, easier
New guidelines from the American Academy of Neurology identify the most effective treatments for amyotrophic lateral sclerosis (ALS), often called Lou Gehrig's disease. The guidelines are published in the October 13, 2009, issue of Neurology®, the medical journal of the American Academy of Neurology.
Researchers find demand for cosmetic and surgical procedures in dermatologic surgery rising rapidly
Researchers from Boston University School of Medicine (BUSM) and the Laser and Skin Cancer Center of Indiana, (Carmel, Indiana), found that there has been a dramatic increase in the number of procedures performed and patient demand for dermatologic health care since 2000.
Argonne researchers develop method that aims to stabilize antibodies
Researchers at the U.S. Department of Energy's Argonne National Laboratory have developed a systematic method to improve the stability of antibodies.
Dysport proves safe, effective anti-wrinkle treatment, UT Southwestern plastic surgeons find
The new anti-wrinkle facial filler Dysport, which could be used as an alternative to Botox, noticeably reduced frown lines between the eyes, according to users and independent reviewers in a study involving plastic surgeons at UT Southwestern Medical Center.
Nose-spray vaccine against botulism effective in first tests
A preclinical study found a new nasal spray vaccine to provide complete protection against a major botulism toxin, according to a study published today in the Nature journal Gene Therapy.
Scientists Reveal Structure of New Botulism Nerve Toxin Subtype
cientists at the U.S. Department of Energy's (DOE) Brookhaven National Laboratory have determined the atomic-level structure of a third subtype of botulinum neurotoxin - a deadly toxin produced by certain bacteria that causes the disease botulism, and is also used in cosmetic and therapeutic applications such as reducing wrinkles and calming a hyperactive bladder.
Advance offers revolution in food safety testing
Microbiologists at Oregon State University have developed a new technology to detect illness-causing bacteria - an advance that could revolutionize the food industry, improving the actual protection to consumers while avoiding the costly waste and massive recalls of products that are suspected of bacterial contamination but are perfectly safe.
American Pain Society's low back guideline expanded to cover interventional procedures
For low-back pain patients and their doctors, the American Pain Society, www.ampainsoc.org, said today it is expanding its evidence-based, clinical practice guideline on diagnosis and treatment of chronic low back pain to include recommendations on surgery and other interventional treatments.
Researchers develop new ultrasensitive assay to detect most poisonous substance known
Scientists at City of Hope and the California Department of Public Health have developed a new ultrasensitive assay to detect botulinum neurotoxin.
Scientists Determine Drug Target for the Most Potent Botulinum Neurotoxin
Botulinum neurotoxin -- responsible for the deadly food poisoning disease botulism and for the beneficial effects of smoothing out facial wrinkles - can also be used as a dreaded biological weapon.
More Botulinum Current Events and Botulinum News Articles
 |
Procedures in Cosmetic Dermatology Series: Botulinum Toxin with DVD by Alastair Carruthers MA BM BCh FRCP(LON) FRCPC (Author), Jean Carruthers MD FRCSC (Author) This title in the PROCEDURES IN COSMETIC DERMATOLOGY SERIES presents up-to-the-minute, practical guidance on botulinum toxin injection techniques shaping today's practice. Succinctly written and lavishly illustrated, it focuses on procedural how-to's and offers step-by-step advice on proper techniques, pitfalls, and tricks of the trade-so you can refine and hone your skills...and expand your surgical repertoire. You'll find current, to-the-point guidance on the cosmetic use of the toxin - edited by pioneers in the field, Drs. Jean and Alastair Carruthers. Implement the newest procedures into your practice immediately and confidently-with the outstanding guidance you'll find in this volume of the PROCEDURES IN COSMETIC DERMATOLOGY SERIES. Covers the hottest topics-including botox... |
 |
Botulinum Toxin in Aesthetic Medicine by Mauricio de Maio (Author), Berthold Rzany (Author) Written by two renowned international experts in the field, this book gives a brilliant overview of the use of botulinum toxin A in aesthetic medicine, including patient selection and evaluation, as well as rules and requirements. It provides hands-on information for the most common indications, such as forehead and glabella, lateral brow lift, crow’s feet and lower eyelid, bunny lines and marionette lines, nose and nasolabial folds, cheeks and "gummy smile," upper and lower lip, and the chin and neck. Also included are the more advanced indications, such as facial asymmetries, Btx-A lifting and microinjection techniques. Combination therapy and complications are also covered and a section with tips and tricks makes this book an invaluable resource for the... |
|
Botulinum Journal by Inderscience Enterprises Ltd | |
 |
Botulinum Toxin Injection Guide by Lb (Author), M.D. Odderson (Author) Botilinum toxin is used frequently by physiatrists for the treatment of patients with migraines, tics, spasms, dystonia, hyperhidrosis (excessive sweating), and pain. Botulinum Toxin Injection Guide by Ib R. Odderson, MD, PhD, is the first comprehensive manual that covers botulinum toxin injections for neurologic conditions and their wide range of practical applications. |
 |
Pretox 20 (1) 1.7 oz. Injection-Free alternative to Botulinum Toxin by Medik8 Injection-Free alternative to Botulinum Toxin treatment. Muscle Relaxant Gel in Liposome Delivery System. Muscles contract when they receive a neurotransmitter release from a nerve. Like Botulinum Toxin A, Pretox releases the amount of nerve stimulation on the local muscle tissue being targeted but unlike Botulinum Toxin A, Pretox does not paralyse the muscle completely. Instead it gently and temporarily reduces the strength of specific muscle contractions thus the formulation of new lines and wrinkles in reduced and old lines appear much less prominent - leaving you with smoother younger looking skin. |
 |
C. Botulinum Zoozither (Primary Contributor) |
 |
Making it New Again: Laser Scar Revision and Facial Rejuvenation This talk will focus on new treatments for reducing, and in some cases, eliminating scars from acne and other imperfections in the skin through the use of the newest laser technology. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
 |
Manual of Botulinum Toxin Therapy (Cambridge Medicine) by Daniel Truong (Editor), Dirk Dressler (Editor), Mark Hallett (Editor) The Manual of Botulinum Toxin Therapy provides practical guidance on the use of botulinum toxin in a wide variety of disorders, in many areas of medicine. Using clear line drawings, it describes the relevant injection sites for each condition and gives comparative dosage tables for the various formulations of toxin used in different muscle groups. It also provides the most up-to-date review of the range of applications, including coverage of promising future developments. The emphasis throughout is on technique. This book can be read as a teaching aid, and will also be useful for immediate bedside guidance. This Manual will be of interest to the growing band of clinicians discovering the potential of botulinum toxin, including neurologists, otolaryngologists, urologists,... |
|
Botulinum Toxin in the Management of Facial Spasm [VHS] | |
 |
Botulinum Toxin: Therapeutic Clinical Practice and Science, Expert Consult - Online and Print by Joseph Jankovic MD (Author), Alberto Albanese (Author), M. Zouhair Atassi PhD DSc (Author), J. Oliver Dolly (Author), Mark Hallett MD (Author), Nathaniel H. Mayer (Author) The new, therapeutically-focused Botulinum Toxin presents comprehensive, cross-disciplinary guidance on current practices, covering more than 100 non-cosmetic conditions that occur in neurology, physical medicine and rehabilitation, pain medicine, ophthalmology, gastroenterology, urology, orthopedics, and surgery. International contributors review the current understanding of the biology and cellular mechanisms along with relevant research so you can easily apply them to the pathophysiology of the numerous disorders that botulinum toxin is used to treat-such as botulinum toxin applications for the treatment of cranial-cervical dystonias, motor disorders in cerebral palsy, bruxism and temporomandibular disorders, headache, overactive bladder, chronic pelvic pain syndromes, arthritis joint... |
| © 2009 BrightSurf.com |